Probable Upcoming Sales of Nuvilex, Inc. (NVLX) Cancer Treatments Render Investment in Technology Valuable

[Investor's Daily Update]

Likely Upcoming Sales of Nuvilex, Inc. (NVLX) Cancer Treatments Render
Investment in Technology Valuable

As Nuvilex, Inc. (OTCQB: NVLX) persistently primes for its Phase III
pancreatic cancer trials, the nearly $30-million it has invested in its
unique and one-of-a-kind living cell encapsulation or “Cell-in-a-Box”
technology could be money well spent given the profit in annual sales that
cancer medications generate in the marketplace.

The first area the company is choosing to undertake is advanced pancreatic
cancer – a market that Eli Lilly’s medication Gemzar has overtaken and
yields about $1.4-billion yearly.

Nuvilex has about $25-million invested in two independent Phase II clinical
trials in patients with advanced, inoperable pancreatic cancer using the
mixture of the widely-used anticancer medication, ifosfamide, and
encapsulated cells capable of changing the ifosfamide, into its
“cancer-killing” form as well as for preclinical studies examining the
potential use of the cell encapsulation technology in the progression of
treatments for other cancers and other diseases. Also, the company has
earmarked almost another $2-million into furthering the development of the
“Cell-in-a-Box” technology.

This is a pretty substantial price tag for such a small biotech, but with
the outcomes the company has seen in its two clinical trials, the future
looks very encouraging. In those trials, the outcomes are outperforming the
current gold standard, the aforementioned Eli Lilly’s medicine Gemzar.

Cancer medications are big business, and those medications are even bigger
business when they  work, and when they prolong lives, and so far,
Nuvilex’s cell encapsulation technology has shown it does work and it
does lengthen lives.

A quick scan at the noteworthy outcomes in those two trials shows that with
twenty-seven patients included, a substantial response was seen in that the
use of the living cell encapsulation-ifosfamide grouping helped patients to
a better outcome than that formerly reported with standard
single-medication (Gemzar) therapy.

Outcomes from these trials included; median survival time and one-year
survival rate were almost doubled as compared to historical data for
Gemzar. The harshness of ifosfamide's side effects was lessened because
only one-third of its usual dose was used. No harm to tissues adjacent to
the capsules was recorded. Cells inside the capsules were protected from
harm by the patients’ immune systems. Cells within the capsules were
alive and operative – even after more than two years.

And, this is only the treatment for advanced pancreatic cancer which is as
severe a disease as it gets – how about using this technology as a remedy
for other types of cancer? Nuvilex’s “Cell-in-a-Box” technology could
make its mark perfecting on the industry standard in one sort of cancer
after the other, and when you start to ponder the billions being generated
each year in those medicines, that certainly makes the technology well
worth the investment to date.


To stop receiving these
emails:http://dalledaw.info/unsubscribe.php?M=29060591&C=f4ddb30d6c4e320f9aafb7af995cb9f5&L=71&N=166

View disclaimer
http://dalledaw.info/link.php?M=29060591&N=166&L=3&F=T

10200 Forest Green Blvd, Suite 112, Louisville, Kentucky 40223 U.S.A.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://oss.sgi.com/pipermail/xfs/attachments/20130327/d44b9a29/attachment.html>